Abstract：The emergence of resistance to antituberculosis drugs, particularly the multidrug-resistant tuberculosis (MDR-TB), has become a major public health problem in many countries. China as one of 27 high-burden countries with MDR-TB around the world, MDR-TB and extensively drug-resistant tuberculosis (XDR-TB) become the primary factors to hamper TB control. Second-line anti-tuberculosis agents are the major drugs for the treatment of MDR-TB. A thorough understanding of molecular mechanism of drug resistance of second-line anti-tuberculosis agents can establish a simple and rapid method for detecting the drug resistance of second-line anti-tuberculosis agents and provide a biomolecular basis for developing new anti-tuberculosis drugs, and it is of great value to prevent the further spread of MDR-TB. This paper reviews the great advances in the molecular mechanism of drug resistance of second-line anti-tuberculosis agents in recent years.
胡彦，刘洁，杨春. 结核分枝杆菌二线抗结核药物耐药分子机制研究进展[J]. 实用预防医学, 2017, 24(11): 1405-1409.
HU Yan, LIU Jie, YANG Chun. Progress on molecular mechanism of drug resistance of second-line antituberculosis agents in Mycobacterium tuberculosis. , 2017, 24(11): 1405-1409.
[1] Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China[J]. N Engl J Med, 2012, 366(23):2161-2170. [2] Berning SE. The role of fluoroquinolones in tuberculosis today[J]. Drugs, 2001,61(1):9-18. [3] Piton J, Petrella S, Delarue M, et al. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrAse[J]. PLoS One, 2010, 5(8):e12245. [4] Devasia R, Blackman A, Eden S, et al. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrAse polymorphisms and a gyrA region associated with fluoroquinolone susceptibility[J]. J Clin Microbiol, 2012, 50(4):1390-1396. [5] Takiff HE, Salazar L, Guerrero C, et al.Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations[J].Antimicrob Agents Chemother, 1994, 38(4):773-780. [6] Huang TS, Kunin CM, Shin-Jung Lee S, et al. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre:1995-2003[J]. J Antimicrob Chemother, 2005, 56(6):1058-1062. [7] Zhang Z, Lu J, Wang Y, et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China[J]. Antimicrob Agents Chemother, 2014, 58(1):364-369. [8] Yin X, Yu Z. Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China[J]. J Infect, 2010, 61(2):150-154. [9] Zhao LL, Chen Y, Liu HC, et al. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from China[J]. Antimicrob Agents Chemother, 2014, 58(4):1997-2005. [10] Shi R, Zhang J, Li C, et al. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing[J]. J Clin Microbiol, 2006, 44(12):4566-4568. [11] Maruri F, Sterling TR, Kaiga AW, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system[J]. J Antimicrob Chemother, 2012, 67(4):819-831. [12] Mokrousov I, Otten T, Manicheva O, et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia[J]. Antimicrob Agents Chemother, 2008, 52(8):2937-2939. [13] Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis:classical and new drugs[J]. J Antimicrob Chemother, 2011, 66(7):1417-1430. [14] Kocagz T, Hackbarth CJ, Unsal I, et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra[J]. Antimicrob Agents Chemother, 1996, 40(8):1768-1774. [15] Sun Z, Zhang J, ZhangX, et al. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates[J].Int J Antimicrob Agents, 2008,31(2):115-121. [16] De Rossi E, Aínsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance:an unresolved question[J]. FEMS Microbiol Rev, 2006, 30(1):36-52. [17] Jugheli L, Bzekalava N, de Rijk P, et al. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene[J]. Antimicrob Agents Chemother, 2009, 53(12):5064-5068. [18] Suzuki Y, Katsukawa C, Tamaru A,et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene[J]. J Clin Microbiol, 1998, 36(5):1220-1225. [19] Hu Y, Hoffner S, Wu L, et al. Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in rural China[J]. Antimicrob Agents Ch, 2013, 57(8):3857-3863. [20] Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis[J] . Antimicrob Agents Chemother, 2005, 49(8):3192-3197. [21] Zhang Z, Liu M, Wang Y, et al. Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China[J]. Eur J Clin Microbiol Infect Dis, 2014, 33(11):1959-1966. [22] Georghiou SB, Magana M, Garfein RS, et al. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin:a systematic review[J]. PLoS One, 2012, 7(3):e33275. [23] Yuan X, Zhang T, Kawakami K, et al. Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China[J]. J Clin Microbiol, 2012, 50(7):2404-2413. [24] Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis[J].Antimicrob Agents Chemother, 2011, 55(5):2032-2041. [25] Reeves AZ, Sikes RD, Metchock B, et al. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase Eis confers kanamycin resistance in Mycobacterium tuberculosis[J]. Proc Natl Acad Sci U S A, 2009,106(47):20004-20009. [26] Johansen SK, Maus CE, Plikaytis BB, et al. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs[J]. Mol Cell, 2006, 23(2):173-182. [27] Engstrm A, Perskvist N, Werngren J, et al. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis[J]. J Antimicrob Chemother, 2011, 66(6):1247-1254. [28] Baulard AR, Betts JC, Engohang-Ndong J, et al. Activation of the pro-drug ethionamide is regulated in mycobacteria[J]. J Biol Chem, 2000, 275(36):28326-38331. [29] Morlock GP, Metchock B, Sikes D, et al. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates[J]. Antimicrob Agents Chemother, 2003, 47(12):3799-3805. [30] Vale N, Gomes P, Santos HA. Metabolism of the antituberculosis drug ethionamide[J]. Curr Drug Metab, 2013, 14(1):151-158. [31] Vilchèze C, Jacobs WR Jr. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities[J]. Microbiol Spectr, 2014, 2(4):MGM2-0014-2013. [32] Brossier F, Veziris N, Truffot-Pernot C, et al. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2011, 55(1):355-360. [33] Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis[J]. Science, 1994, 263(5144):227-230. [34] Marrakchi H, Lanéelle G, Quémard A. inhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II[J]. Microbiology, 2000, 146(Pt2):289-296. [35] Vilchèze C, Weisbrod TR, Chen B, et al. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria[J]. Antimicrob Agents Chemother, 2005, 49(2):708-720. [36] Cardoso RF, Cardoso MA, Leite CQ, et al. Characterization of ndh gene of isoniazid resistant and susceptible Mycobacterium tuberculosis isolates from Brazil [J]. Mem Inst Oswaldo Cruz, 2007, 102(1):59-61. [37] Vilchèze C, Av-Gay Y, Attarian R, et al. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis[J]. Mol Microbiol, 2008, 69(5):1316-1329. [38] Rueda J, Realpe T, Mejia GI, et al. Genotypic analysis of genes associated with independent resistance and cross-resistance to isoniazid and ethionamide in Mycobacterium tuberculosis clinical isolates[J]. Antimicrob Agents Chemother, 2015, 59(12):7805-7810. [39] Projahn M, Kser CU, Homolka S, et al. Polymorphisms in isoniazid and prothionamide resistance genes of the Mycobacterium tuberculosis complex[J]. Antimicrob Agents Chemother, 2011, 55(9):4408-4411. [40] Minato Y, Thiede JM, Kordus SL, et al. Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance[J]. Antimicrob Agents Chemother, 2015, 59(9):5097-5106. [41] Zheng J, Rubin EJ, Bifani P, et al. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis[J]. J Biol Chem, 2013, 288(32):23447-23456. [42] Zhao F, Wang XD, Erber LN, et al. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis[J]. Antimicrob Agents Chemother, 2014, 58(3): 1479-1487. [43] Zhang XB, Liu LG, Zhang Y, et al. Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012[J]. Antimicrob Agents Chemother, 2015, 59(2):1320-1324. [44] Rengarajan J, Sassetti CM, Naroditskaya V, et al. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria[J]. Mol Microbiol, 2004, 53(1):275-282. [45] Fivian-Hughes AS, Houghton J, Davis EO. Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid [J]. Microbiology, 2012, 158(Pt 2):308-318. [46] Zhang ZD, Zhao YL, Li ZH, et al. Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. Tuberculosis[J].Chin J Tub Res Dis, 2007, 30(9):683-685. [47] Desjardins CA, Cohen KA, Munsamy V, et al. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance[J]. Nat Genet, 2016, 48(5):544-551. [48] Feng Z, Barletta RG. Roles of Mycobacterium smegmatis D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine[J]. Antimicrob Agents Chemother, 2003, 47(1):283-291. [49] Hong W, Chen L, Xie J. Molecular basis underlying Mycobacterium tuberculosis D-cycloserine resistance. Is there a role for ubiquinone and menaquinone metabolic pathways?[J]. Expert Opin Ther Targets, 2014, 18(6):691-701.
2017, Vol. 24 
